论文信息 - LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) - 字舞流文

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

P. Galle | Ruifeng Xu | J. Llovet | R. Finn | S. Qin | T. Meyer | A. Siegel | P. Merle | B. Ryoo | L. Dubrovsky | J. Edeline | K. Mody | A. Wang | Z. Ren | A. Cheng | M. Kudo | S. Kaneko | H. Kumada | M. Ikeda | A. Wang